Wells Fargo & Company Increases NeuroPace (NASDAQ:NPCE) Price Target to $17.00

NeuroPace (NASDAQ:NPCE) had its target price boosted by research analysts at Wells Fargo & Company from $13.00 to $17.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 19.80% from the company’s current price.

A number of other research firms have also recently weighed in on NPCE. JPMorgan Chase & Co. boosted their target price on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. UBS Group began coverage on NeuroPace in a research note on Tuesday, January 21st. They set a “buy” rating and a $17.00 price target for the company. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

NeuroPace Stock Down 3.4 %

Shares of NPCE traded down $0.50 during trading hours on Thursday, hitting $14.19. 462,912 shares of the company were exchanged, compared to its average volume of 167,953. The company has a market cap of $423.57 million, a PE ratio of -14.19 and a beta of 2.02. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. The firm’s 50 day moving average is $11.65 and its 200-day moving average is $8.78. NeuroPace has a 52 week low of $5.45 and a 52 week high of $18.15.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07. The firm had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same period last year, the company earned ($0.28) EPS. On average, equities research analysts forecast that NeuroPace will post -1 EPS for the current fiscal year.

Insider Buying and Selling at NeuroPace

In other news, insider Martha Morrell sold 3,200 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $15.01, for a total transaction of $48,032.00. Following the completion of the sale, the insider now owns 87,062 shares in the company, valued at approximately $1,306,800.62. This represents a 3.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 22.20% of the company’s stock.

Institutional Investors Weigh In On NeuroPace

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Palumbo Wealth Management LLC acquired a new stake in NeuroPace during the 4th quarter worth approximately $129,000. Financial Advocates Investment Management grew its stake in shares of NeuroPace by 27.8% in the 4th quarter. Financial Advocates Investment Management now owns 23,000 shares of the company’s stock valued at $257,000 after purchasing an additional 5,000 shares during the last quarter. KCK LTD. acquired a new stake in shares of NeuroPace in the 4th quarter valued at approximately $58,981,000. JPMorgan Chase & Co. increased its stake in NeuroPace by 106.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock valued at $84,000 after purchasing an additional 6,181 shares in the last quarter. Finally, Barclays PLC increased its stake in shares of NeuroPace by 346.0% during the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock worth $144,000 after purchasing an additional 16,007 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.